In this research study, the investigators are evaluating the clinical benefit of everolimus
in cancer patients with inactivating TSC1 or TSC2 mutations or activating MTOR mutations.
This research study is a Phase II clinical trial, which tests the safety and effectiveness of
an investigational drug called everolimus to learn whether the drug works in treating a
specific cancer. "Investigational" means that the drug is being studied. It also means that
the FDA (the U.S. Food and Drug Administration) has not yet approved everolimus for your type
of cancer.
Everolimus is a drug that may stop cancer cells from growing by blocking an important factor
(mTOR) involved in the growth of cells. This drug has been used in treatment for other
cancers and is approved by the Food and Drug Administration for treatment of several types of
cancer, including renal cell carcinoma. Treatment with this drug has been associated with
responses in some patients whose cancers had mutations in TSC1 or TSC2. The investigators
think that patients whose tumors have mutations in TSC1 or TSC2 may have a good chance of
responding to treatment with drugs like everolimus.